These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 22262194)
21. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907 [TBL] [Abstract][Full Text] [Related]
22. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831 [TBL] [Abstract][Full Text] [Related]
23. Cytokines regulate matrix metalloproteinases in human uterine endometrial fibroblast cells through a mechanism that does not involve increases in extracellular matrix metalloproteinase inducer. Braundmeier AG; Nowak RA Am J Reprod Immunol; 2006 Sep; 56(3):201-14. PubMed ID: 16911716 [TBL] [Abstract][Full Text] [Related]
24. Effect of glycosaminoglycans on matrix metalloproteinases in type II collagen-induced experimental arthritis. Sandya S; Sudhakaran PR Exp Biol Med (Maywood); 2007 May; 232(5):629-37. PubMed ID: 17463159 [TBL] [Abstract][Full Text] [Related]
25. [Matrix metalloproteinases and their inhibitors, modulators of neuro-immune interactions and of pathophysiological processes in the nervous system]. Khrestchatisky M; Jourquin J; Ogier C; Charton G; Bernard A; Tremblay E; Rivera S J Soc Biol; 2003; 197(2):133-44. PubMed ID: 12910628 [TBL] [Abstract][Full Text] [Related]
26. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790 [TBL] [Abstract][Full Text] [Related]
27. Detection of serum MMPs in tumor-bearing hamsters. Iki K; Takeo T; Kubozoe T; Aoki S; Hayashi J; Tsunoda T J Hepatobiliary Pancreat Surg; 2002; 9(4):478-84. PubMed ID: 12483270 [TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501 [TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Matsuyama A; Sakai N; Ishigami M; Hiraoka H; Kashine S; Hirata A; Nakamura T; Yamashita S; Matsuzawa Y Circulation; 2003 Sep; 108(12):1469-73. PubMed ID: 12952836 [TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinases in blood from patients with LAM. Odajima N; Betsuyaku T; Nasuhara Y; Inoue H; Seyama K; Nishimura M Respir Med; 2009 Jan; 103(1):124-9. PubMed ID: 18760908 [TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176 [TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833 [TBL] [Abstract][Full Text] [Related]
33. Circulating matrix metalloproteinases and their inhibitors in hypertension. Fontana V; Silva PS; Gerlach RF; Tanus-Santos JE Clin Chim Acta; 2012 Apr; 413(7-8):656-62. PubMed ID: 22245508 [TBL] [Abstract][Full Text] [Related]
34. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109 [TBL] [Abstract][Full Text] [Related]
35. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449 [TBL] [Abstract][Full Text] [Related]
37. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151 [TBL] [Abstract][Full Text] [Related]
38. Altered expression of matrix metalloproteinases and their tissue inhibitors as possible contributors to corneal droplet formation in climatic droplet keratopathy. Holopainen JM; Serra HM; Sánchez MC; Sorsa T; Zalentein WN; Barcelona PF; Moilanen JA; Tervahartiala T; Tervo TM; Cafaro TA; Virtanen I; Urrets-Zavalia EA; Bhattacharya SK; Urrets-Zavalia JA Acta Ophthalmol; 2011 Sep; 89(6):569-74. PubMed ID: 19900203 [TBL] [Abstract][Full Text] [Related]
39. Role of matrix metalloproteinases in delayed cortical responses after stroke. Zhao BQ; Wang S; Kim HY; Storrie H; Rosen BR; Mooney DJ; Wang X; Lo EH Nat Med; 2006 Apr; 12(4):441-5. PubMed ID: 16565723 [TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Verslegers M; Lemmens K; Van Hove I; Moons L Prog Neurobiol; 2013 Jun; 105():60-78. PubMed ID: 23567503 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]